[
  {
    "ts": null,
    "headline": "Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?",
    "summary": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=6bd81bd2a3f98df8900a392720a2915ca9fd5b4c4085bdbb6e2bc326a9e049b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756917013,
      "headline": "Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?",
      "id": 136617001,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=6bd81bd2a3f98df8900a392720a2915ca9fd5b4c4085bdbb6e2bc326a9e049b1"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript",
    "summary": "Discover Vertex Pharmaceuticals' latest milestones in CF, pain, and kidney disease therapies.",
    "url": "https://finnhub.io/api/news?id=f1a5cb2dc9dd5609e55ae6f7c0d991bfca545c1e6178fd5dc76f8092da9859e6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756915053,
      "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript",
      "id": 136632019,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Discover Vertex Pharmaceuticals' latest milestones in CF, pain, and kidney disease therapies.",
      "url": "https://finnhub.io/api/news?id=f1a5cb2dc9dd5609e55ae6f7c0d991bfca545c1e6178fd5dc76f8092da9859e6"
    }
  },
  {
    "ts": null,
    "headline": "Here’s Why Vertex Pharmaceuticals (VRTX) is on Loomis Sayles Growth Fund’s Detractors List",
    "summary": "Loomis Sayles, an investment management company, released its “Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund returned 18.58% compared to 17.84% for the Russell 1000 Growth Index. The fund focused on a highly selective, long-term private equity approach to investing. In addition, […]",
    "url": "https://finnhub.io/api/news?id=5b1e9251c8f0af1df5a744b898d84caa57dea09a7e41baf1270da05427f27a24",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756905445,
      "headline": "Here’s Why Vertex Pharmaceuticals (VRTX) is on Loomis Sayles Growth Fund’s Detractors List",
      "id": 136615784,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Loomis Sayles, an investment management company, released its “Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund returned 18.58% compared to 17.84% for the Russell 1000 Growth Index. The fund focused on a highly selective, long-term private equity approach to investing. In addition, […]",
      "url": "https://finnhub.io/api/news?id=5b1e9251c8f0af1df5a744b898d84caa57dea09a7e41baf1270da05427f27a24"
    }
  }
]